NCT01424436View on ClinicalTrials.gov

Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 19, 2010

Primary Completion Date

December 8, 2011

Study Completion Date

December 8, 2011

Conditions
Alzheimer's Disease
Interventions
BIOLOGICAL

GSK933776

1mg/kg dose group

BIOLOGICAL

GSK933776

3mg/kg dose group

BIOLOGICAL

GSK933776

6mg/kg dose group

Trial Locations (7)

52074

GSK Investigational Site, Aachen

68159

GSK Investigational Site, Mannheim

72076

GSK Investigational Site, Tübingen

81675

GSK Investigational Site, Munich

89081

GSK Investigational Site, Ulm

SE-212 24

GSK Investigational Site, Malmo

se-141 86

GSK Investigational Site, Stockholm

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01424436 - Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient | Biotech Hunter | Biotech Hunter